ImmunoVec
ImmunoVec develops programmable DNA with cell-type-specific transcriptional control; the accessible primary disclosure highlights NK cells. It is tracked as adjacent in vivo immune engineering, without assuming that CAR-NK results establish a CAR-T program or clinical stage.
Corporate information
- Company entity
- ImmunoVec
- Headquarters / principal office
- Los Angeles, United States (company announcement location)Announcement location, not an independently confirmed headquarters address. ↗
- Founded
- Not verified
- Ownership / capital status
- Not verifiedARPA-H multiyear award; not equity financing ↗
- Official corporate reference
- https://immunovec.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2025-10-08 · ARPA-H EMBODY award · Up to $40.7 million ↗
Capped multiyear research award, not cash already received or a venture-capital round.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
ImmunoVec develops programmable DNA with cell-type-specific transcriptional control; the accessible primary disclosure highlights NK cells. It is tracked as adjacent in vivo immune engineering, without assuming that CAR-NK results establish a CAR-T program or clinical stage.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.